TOKYO -- Despite a record 2017 profit, Japanese cosmetics company Pola Orbis Holdings is being forced to walk a precarious path with shareholders as suspicion over a family inheritance gains new life and sales struggle in Asian markets.
The Pola Wrinkle Shot Serum facial treatment product has been a big hit among middle-aged and elderly women, driving the company's brisk earnings last year. President Satoshi Suzuki could have boasted about his decision to take a long view and spend 15 years to develop the product. Its first-year sales reached about 13 billion yen ($122 million).
